A world where people do not lose their sight to AMD
Our mission is to find and enable convenient, affordable and accessible solutions to stop AMD in its early stages, before it causes sight loss.
An estimated 196 million people in the world live with AMD, a figure that will increase to 288 million by 2040. Around 10 million people have significant sight loss due to AMD, and that number is expected to rise to 20 million by 2040 .
In the UK there are more than 685,000 people with sight loss caused by late-stage AMD and that will be 1.3 million by 2050.
AMD destroys central vision leaving a person unable to read, drive, or recognise faces. It is associated with social isolation, loneliness, falls, poorer general health and significant mental illness including depression and even suicide.
Our aim is to develop a therapy that will stop or significantly slow progression of AMD into its late, sight-threatening stages - including both dry and wet AMD.
Wet AMD is currently treated by repeated intravitreal (into the eye) injections to slow the development of abnormal blood vessels in the retina, at the back of the eye. Dry AMD is untreatable.
(1) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic
review and meta-analysis
Wan Ling Wong*, Xinyi Su*, Xiang Li, Chui Ming G Cheung, Ronald Klein, Ching-Yu Cheng†, Tien Yin Wong†
Lancet Glob Health 2014; 2: e106–16. Published Online January 3, 2014